| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
28,063 |
23,085 |
$7.70M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,068 |
7,084 |
$1.24M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,483 |
3,206 |
$1.21M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
19,597 |
6,658 |
$858K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,907 |
2,570 |
$683K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
755 |
733 |
$650K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
9,636 |
3,477 |
$484K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
8,098 |
7,383 |
$367K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,083 |
1,496 |
$315K |
| 80053 |
Comprehensive metabolic panel |
19,625 |
17,544 |
$284K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
23,658 |
20,089 |
$265K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,258 |
2,727 |
$236K |
| 84443 |
Thyroid stimulating hormone (TSH) |
7,675 |
7,468 |
$198K |
| 71046 |
Radiologic examination, chest; 2 views |
3,294 |
3,138 |
$192K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
5,452 |
3,897 |
$185K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,699 |
5,801 |
$152K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
1,785 |
1,781 |
$148K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,218 |
2,032 |
$138K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
4,168 |
4,117 |
$132K |
| 70450 |
Computed tomography, head or brain; without contrast material |
563 |
540 |
$129K |
| 97161 |
|
813 |
807 |
$122K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,066 |
2,830 |
$120K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
447 |
442 |
$114K |
| 80061 |
Lipid panel |
6,787 |
6,672 |
$113K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,957 |
1,518 |
$113K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,143 |
1,141 |
$97K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
328 |
326 |
$89K |
| 86618 |
|
1,555 |
1,511 |
$73K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
785 |
754 |
$62K |
| 76376 |
|
5,685 |
4,817 |
$54K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
4,521 |
4,441 |
$51K |
| 84439 |
|
3,269 |
3,184 |
$50K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,183 |
2,097 |
$50K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
288 |
257 |
$49K |
| 84703 |
|
2,491 |
2,310 |
$47K |
| 84484 |
|
2,913 |
2,333 |
$45K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
905 |
639 |
$43K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,121 |
3,508 |
$37K |
| 82728 |
|
1,130 |
1,101 |
$36K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
590 |
569 |
$36K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
590 |
569 |
$36K |
| 87088 |
|
3,158 |
2,898 |
$33K |
| 83690 |
|
2,677 |
2,468 |
$32K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,833 |
2,637 |
$28K |
| 86803 |
|
914 |
895 |
$28K |
| 81001 |
|
1,714 |
1,566 |
$25K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
697 |
694 |
$22K |
| 83735 |
|
2,724 |
2,343 |
$21K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
74 |
73 |
$20K |
| 76830 |
Ultrasound, transvaginal |
95 |
93 |
$19K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
26 |
26 |
$18K |
| 87070 |
|
740 |
716 |
$17K |
| 84466 |
|
540 |
536 |
$16K |
| ATP14 |
|
6,656 |
5,350 |
$16K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
388 |
371 |
$16K |
| 73630 |
|
126 |
120 |
$16K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
258 |
248 |
$16K |
| 84182 |
|
297 |
290 |
$15K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
98 |
92 |
$15K |
| 81000 |
|
3,049 |
2,741 |
$14K |
| J2704 |
Injection, propofol, 10 mg |
2,133 |
1,400 |
$13K |
| 82607 |
|
341 |
336 |
$13K |
| 86141 |
|
863 |
810 |
$13K |
| 86140 |
|
721 |
676 |
$10K |
| 73610 |
|
72 |
70 |
$10K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
101 |
90 |
$9K |
| 59025 |
Fetal non-stress test |
46 |
28 |
$9K |
| 85610 |
|
4,090 |
2,461 |
$8K |
| 83540 |
|
594 |
586 |
$8K |
| 86666 |
|
71 |
60 |
$8K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,440 |
1,354 |
$8K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
376 |
356 |
$8K |
| 71045 |
Radiologic examination, chest; single view |
551 |
506 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,043 |
2,300 |
$7K |
| 81003 |
|
802 |
770 |
$7K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
200 |
185 |
$7K |
| 85652 |
|
624 |
599 |
$6K |
| 86780 |
|
323 |
319 |
$6K |
| 0003A |
|
164 |
162 |
$6K |
| 81002 |
|
1,443 |
1,393 |
$6K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
167 |
86 |
$6K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,671 |
1,755 |
$5K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
104 |
104 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
81 |
71 |
$5K |
| 99215 |
Prolong outpt/office vis |
91 |
88 |
$4K |
| 90686 |
|
277 |
277 |
$4K |
| 87340 |
|
249 |
234 |
$4K |
| ATP17 |
|
1,496 |
1,343 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
8,361 |
6,948 |
$3K |
| 0002A |
|
57 |
57 |
$3K |
| 80076 |
|
325 |
311 |
$3K |
| 73562 |
|
25 |
24 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
68 |
68 |
$3K |
| 83605 |
|
579 |
494 |
$3K |
| 87468 |
|
189 |
188 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
121 |
121 |
$3K |
| 0001A |
|
45 |
45 |
$3K |
| 87469 |
|
178 |
177 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,347 |
2,009 |
$2K |
| 85730 |
|
509 |
477 |
$2K |
| 86706 |
|
180 |
176 |
$2K |
| 87186 |
|
289 |
267 |
$2K |
| J7050 |
Infusion, normal saline solution, 250 cc |
678 |
461 |
$2K |
| ATP08 |
|
1,710 |
1,330 |
$2K |
| 97162 |
|
15 |
15 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
13 |
13 |
$2K |
| 90715 |
|
29 |
27 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
45 |
24 |
$2K |
| 83655 |
|
43 |
42 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
157 |
139 |
$2K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
13 |
12 |
$2K |
| 83880 |
|
185 |
160 |
$1K |
| 87631 |
|
35 |
33 |
$1K |
| 84702 |
|
29 |
25 |
$1K |
| 86704 |
|
122 |
118 |
$1K |
| 71271 |
|
12 |
12 |
$1K |
| ATP15 |
|
570 |
438 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
15 |
15 |
$1K |
| 85027 |
|
109 |
89 |
$1K |
| 0124A |
|
32 |
32 |
$1K |
| 86709 |
|
147 |
133 |
$934.84 |
| 80164 |
|
244 |
225 |
$897.93 |
| 0013A |
|
15 |
15 |
$866.83 |
| 82077 |
|
30 |
27 |
$840.95 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
275 |
238 |
$746.26 |
| 97035 |
|
36 |
13 |
$696.24 |
| 0134A |
|
15 |
15 |
$673.39 |
| 81513 |
|
26 |
16 |
$629.00 |
| 85007 |
|
94 |
77 |
$425.84 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
167 |
123 |
$413.60 |
| 87486 |
|
13 |
13 |
$398.86 |
| 86850 |
|
14 |
14 |
$355.55 |
| 84100 |
|
148 |
120 |
$344.62 |
| 86769 |
|
13 |
12 |
$252.78 |
| 82570 |
|
16 |
15 |
$222.78 |
| 86901 |
|
15 |
14 |
$209.76 |
| 71250 |
|
24 |
24 |
$209.71 |
| 99406 |
|
26 |
26 |
$194.49 |
| 87634 |
|
16 |
15 |
$192.09 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
14 |
14 |
$167.83 |
| 86900 |
|
15 |
14 |
$166.08 |
| 86480 |
|
38 |
36 |
$164.01 |
| 87481 |
|
26 |
16 |
$154.75 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
26 |
16 |
$154.75 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
161 |
147 |
$119.86 |
| 82962 |
|
36 |
25 |
$99.23 |
| 87040 |
|
39 |
26 |
$95.85 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
12 |
12 |
$70.06 |
| ATP03 |
|
12 |
12 |
$61.65 |
| ATP02 |
|
38 |
37 |
$32.22 |
| 84153 |
|
12 |
12 |
$16.78 |
| 84520 |
|
139 |
132 |
$7.68 |
| 82565 |
|
151 |
146 |
$5.29 |
| G0008 |
Administration of influenza virus vaccine |
14 |
14 |
$3.87 |
| 82248 |
|
29 |
28 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
52 |
51 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
60 |
58 |
$0.00 |
| 91300 |
|
240 |
230 |
$0.00 |
| 91312 |
|
17 |
17 |
$0.00 |
| 84481 |
|
24 |
20 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
15 |
13 |
$0.00 |
| 91313 |
|
15 |
15 |
$0.00 |
| 91301 |
|
17 |
16 |
$0.00 |